Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis

NCT00160693 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00160693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2003
Completion date
February 28, 2011
Enrollment
402 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis